Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7515)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Oct 28, 2016 (publication date) through Dec 1, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Radiology
ISSN
1949-8470
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Aprile C, Persico MG, Lodola L, Buroni FE. Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold. World J Radiol 2016; 8(10): 816-818 [PMID: 27843540 DOI: 10.4329/wjr.v8.i10.816] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8470/full/v8/i10/816.htm |
| Number | Citing Articles |
| 1 |
Renato Costa, Davide Cardile, Alessandra Murabito, Vincenzo Tripoli, Francesco Verderame. Ra223 in bone metastases with osteolytic activity. World Journal of Nuclear Medicine 2018; 17(02): 116 doi: 10.4103/wjnm.WJNM_22_17
|
| 2 |
Inês A. Marques, Ana M. Abrantes, Ana S. Pires, Ana R. Neves, Francisco J. Caramelo, Tiago Rodrigues, Paulo Matafome, Edgar Tavares-da-Silva, Ana C. Gonçalves, Cristiana C. Pereira, João P. Teixeira, Raquel Seiça, Grancinda Costa, Arnaldo Figueiredo, Maria F. Botelho. Kinetics of radium-223 and its effects on survival, proliferation and DNA damage in lymph-node and bone metastatic prostate cancer cell lines. International Journal of Radiation Biology 2021; 97(5): 714 doi: 10.1080/09553002.2021.1906462
|
| 3 |
Robert B. Den, Daniel George, Christopher Pieczonka, Megan McNamara. Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer. American Journal of Clinical Oncology 2019; 42(4): 399 doi: 10.1097/COC.0000000000000528
|